<DOC>
	<DOCNO>NCT01770158</DOCNO>
	<brief_summary>This non-interventional multi-center study ( NIS ) adult patient AML first complete remission measurable minimal residual disease ( MRD ) . Patients eligible gene status already determine previous induction consolidation therapy AML show carrier NPM1 , CBFÎ²-MYH11 , MLL-AF9 mutation . The study objective observe impact pre-emptive therapy histamine dihydrochloride ( HDC ) interleukin-2 ( IL-2 ) regard ass leukemia-free survival/time relapse monitor MRD level trend time . HDC IL-2 approve drug AML patient first complete remission . Therapy administer 10 treatment cycle outline Summary Product Characteristics .</brief_summary>
	<brief_title>Maintenance Therapy With Histamine Dihydrochloride Interleukin-2 Adult Acute Myeloid Leukemia ( AML ) Patients With Measurable Minimal Residual Disease ( MRD ) - Non-interventional Study ( NIS )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patient eligibility criterion accordance summary Product Characteristics : Patients confirm diagnosis acute myeloid leukemia accord World Health Organization ( WHO ) classification ( include de novo AML , tAML sAML ) first complete remission ( define less 5 % blast normocellular bone marrow assess prior treatment start ) AMLSG BiO participation incl . favourable opinion Presence NPM1 mutation , CBFBMYH11 MLLAF9 fusion gene assess one central AMLSG reference laboratory . Measurable MRD value ( nonnegative value consolidation therapy increase value threshold followup complete remission ) The patient must inform observation write informed consent regard data privacy obtain . Consent registration , storage process individual diseasecharacteristics course well information family physician treat physician observation participation No continue systemic treatment clonidine , steroid , and/or H2 receptor block agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>Histamine Dihydrochloride</keyword>
	<keyword>Interleukin-2</keyword>
</DOC>